09:52 AM EST - Paladin Labs Inc. : and Isotechnika Pharma Inc. announced today that they have submitted the dossier and received screening acceptance for Voclera(TM) (voclosporin) for approval in the Canadian market. Voclera is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis. Paladin Labs Inc.
shares T.PLB are trading down $0.25 at $34.25.
